How to Illuminate the Druggable Genome Using Pharos
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Pharos is an integrated web‐based informatics platform for the analysis of data aggregated by the Illuminating the Druggable Genome (IDG) Knowledge Management Center, an NIH Common Fund initiative. The current version of Pharos (as of October 2019) spans 20,244 proteins in the human proteome, 19,880 disease and phenotype associations, and 226,829 ChEMBL compounds. This resource not only collates and analyzes data from over 60 high‐quality resources to generate these types, but also uses text indexing to find less apparent connections between targets, and has recently begun to collaborate with institutions that generate data and resources. Proteins are ranked according to a knowledge‐based classification system, which can help researchers to identify less studied “dark” targets that could be potentially further illuminated. This is an important process for both drug discovery and target validation, as more knowledge can accelerate target identification, and previously understudied proteins can serve as novel targets in drug discovery. Two basic protocols illustrate the levels of detail available for targets and several methods of finding targets of interest. An Alternate Protocol illustrates the difference in available knowledge between less and more studied targets. © 2020 by John Wiley & Sons, Inc. Basic Protocol 1: Search for a target and view details Alternate Protocol: Search for dark target and view details Basic Protocol 2: Filter a target list to get refined results
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“The druggable genome was defined as “the subset of the (cid:2) 30,000 genes in the human genome that express proteins potentially able to bind drug-like molecules” (Hopkins & Groom, 2002).”
BackgroundRouillard, A. D., Gundersen, G. W., Fernandez, N. F., Wang, Z., Monteiro, C. D., McDermott, M. G., & Ma’ayan, A. (2016) · Database · doi:10.1093/database/baw100 · Cited by 1,515
Architecture of the human interactome defines protein communities and disease networks
Huttlin, E. L., Bruckner, R. J., Paulo, J. A., Cannon, J. R., Ting, L., Baltier, K., Colby, G., Gebreab, F., Gygi, M. P., Parzen, H., et al. (2017) · Nature · doi:10.1038/nature22366 · Cited by 1,437 · cited 1×
“…fractional publication count (Pletscher-Frankild et al., 2015), available antibodies (from antibodype-dia.com), listed protein-protein interactions (Fabregat et al., 2016; Huttlin et al., 2017; Szklarczyk et al., 2019), and knowledge availability (based on Harmonizome; Rouillard et al., 2016).”
BackgroundOnline Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders
Hamosh, A. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.52 · Cited by 762
DISEASES: Text mining and data integration of disease–gene associations
Pletscher-Frankild, S., Pallejà, A., Tsafou, K., Binder, J. X., & Jensen, L. J. (2015) · Methods · doi:10.1016/j.ymeth.2014.11.020 · Cited by 591
Edwards, A. M., Isserlin, R., Bader, G. D., Frye, S. V., Willson, T. M., & Yu, F. H. (2011) · Nature · doi:10.1038/470163a · Cited by 411 · cited 2×
“Tbio targets are targets that have been referenced in the literature and have GeneRIF annotations, antibodies, and molecular or biological function data and phenotypes.”
BackgroundUnexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.14 · Cited by 378 · cited 5×
“All targets in Pharos are categorized according to their “target development level” (TDL), a knowledge-based classification for human proteins (Oprea, Bologa, et al., 2018) that can be used to explore the “dark” genome (Oprea, 2019).”
BackgroundInfluentialSelf-citationPharos: collating protein information to shed light on the druggable genome
Nguyen, D.-T., Mathias, S., Bologa, C., Brunak, S., Fernandez, N., Gaulton, A., Hersey, A., Holmes, J., Jensen, L. J., Karlsson, A., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1072 · Cited by 279
Self-citationGlimmers in illuminating the druggable genome
Rodgers, G., Austin, C., Anderson, J., Pawlyk, A., Colvis, C., Margolis, R., & Baker, J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.252 · Cited by 126 · cited 2×
“Tbio targets are targets that have been referenced in the literature and have GeneRIF annotations, antibodies, and molecular or biological function data and phenotypes.”
BackgroundTIN-X: target importance and novelty explorer
Cannon, D. C., Yang, J. J., Mathias, S. L., Ursu, O., Mani, S., Waller, A., Schürer, S. C., Jensen, L. J., Sklar, L. A., Bologa, C. G., et al. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx200 · Cited by 34 · cited 1×
“…several identifiers, such as target development level (TDL; Oprea, Bologa, et al., 2018), target family, computed target novelty (TIN-X) score (Cannon et al., 2017), fractional publication count (Pletscher-Frankild et al., 2015), available antibodies (from antibodype-dia.com), listed…”
BackgroundSelf-citation
Cited by
Groza, T., Gomez, F. L., Mashhadi, H. H., Muñoz-Fuentes, V., Gunes, O., Wilson, R., Cacheiro, P., Frost, A., Keskivali-Bond, P., Vardal, B., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac972 · Cited by 413
“statistical analysis of long-term series (22,23,31–34) Informatics users Access all, or partial, datasets for inclusion in their own resource set Monarch Initiative (9); Illuminating the Druggable Genome (35); OpenTargets (36) Funding bodies and”
BackgroundTCRD and pharos 2021: mining the human proteome for disease biology
Sheils, T. K., Mathias, S. L., Kelleher, K. J., Siramshetty, V. B., Nguyen, D.-T., Bologa, C. G., Jensen, L. J., Vidović, D., Koleti, A., Schürer, S. C., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa993 · Cited by 160
“Additional protocols for extracting available data for specific targets of interest, as well the differences in knowledge availability between understudied and more studied targets, are discussed elsewhere (46).”
BackgroundSelf-citationPharos 2023: an integrated resource for the understudied human proteome
Kelleher, K. J., Sheils, T. K., Mathias, S. L., Yang, J. J., Metzger, V. T., Siramshetty, V. B., Nguyen, D.-T., Jensen, L. J., Vidović, D., Schürer, S. C., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1033 · Cited by 137
Self-citationDark kinase annotation, mining, and visualization using the Protein Kinase Ontology
Soleymani, S., Gravel, N., Huang, L.-C., Yeung, W., Bozorgi, E., Bendzunas, N. G., Kochut, K. J., & Kannan, N. (2023) · PeerJ · doi:10.7717/peerj.16087 · Cited by 13
Metadata
- Authors
- Sheils, T., Mathias, S. L., Siramshetty, V. B., Bocci, G., Bologa, C. G., Yang, J. J., Waller, A., Southall, N., Nguyen, D., & Oprea, T. I.
- Venue
- Current Protocols in Bioinformatics
- Publisher
- Wiley
- Published
- 2020-01-03
- Volume
- 69
- Issue
- 1
- Pages
- e92-e92
- ISSN
- 1934-3396 (ISSN-L)
- 1934-340X
- OpenAlex
- W2998400169
- Cited by
- 45
- References
- 10
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How to Illuminate the Druggable Genome Using Pharos. https://app.cochat.ai/papers/10.1002/cpbi.92
- The paper
- Sheils, T., Mathias, S. L., Siramshetty, V. B., Bocci, G., Bologa, C. G., Yang, J. J., Waller, A., Southall, N., Nguyen, D., & Oprea, T. I. (2020). How to Illuminate the Druggable Genome Using Pharos. Current Protocols in Bioinformatics. https://doi.org/10.1002/cpbi.92
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.